Immuron Limited (AU:IMC) has released an update.
Immuron Limited’s CEO, Steven Lydeamore, will participate in a fireside chat at the Maxim Virtual Healthcare Conference, highlighting the company’s innovative work in developing polyclonal antibodies for infectious diseases. Their flagship product, Travelan®, aims to reduce travelers’ diarrhea risk by using hyperimmune bovine antibodies. Immuron is also advancing IMM-529 for Clostridioides difficile infection, showcasing promising results in pre-clinical studies.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
